By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Agents for pulmonary hypertension > Epoprostenol > Epoprostenol Dosage
Agents for pulmonary hypertension
https://themeditary.com/dosage-information/epoprostenol-dosage-11180.html

Epoprostenol Dosage

Drug Detail:Epoprostenol (Epoprostenol [ ee-poe-prost-en-ol ])

Drug Class: Agents for pulmonary hypertension

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Pulmonary Hypertension

Initial dose: 2 ng/kg/min via continuous IV infusion and titrate up in increments of 2 ng/kg/min every 15 minutes or longer until a tolerance limit is established or further increases in infusion rate not clinically warranted

Comments:

  • If the initial infusion rate is not tolerated, a lower dose may be used.
  • If dose-limiting pharmacologic effects occur, decrease infusion rate until this drug is tolerated.

Use: For the treatment of PAH (WHO Group 1) to improve exercise capacity; studies establishing efficacy included predominately patients with New York Heart Association (NYHA) Class III to IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated connective tissue disorders

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Changes in the chronic infusion rate should be based on persistence, recurrence, or worsening of the patient's symptoms of pulmonary hypertension and the occurrence of adverse events due to excessive doses of epoprostenol. In general, increases in dose from the initial chronic dose should be expected.

PAH symptoms which persist or recur after improving:

  • Consider increasing the infusion in increments of 1 to 2 ng/kg/min at intervals of at least 15 minutes
  • Following establishment of a new chronic infusion rate, observe patient and monitor standing and supine blood pressure and heart rate for several hours to ensure that the new dose is tolerated.

Occurrence of dose-limiting pharmacologic events:
  • Dose decreases should occur gradually in 2 ng/kg/min decrements every 15 minutes or longer until dose-limiting effects are resolved
  • Adverse events may occasionally resolve without dose adjustments
  • Avoid abrupt withdrawal or sudden large reductions in infusion rates

Patients receiving lung transplants: Taper dose after initiation of cardiopulmonary bypass

Elderly: Cautious dose selection recommended due to increased likelihood of concomitant hepatic, renal, or cardiac dysfunctions or concomitant disease or other drug therapy.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Once prepared as directed, administer by continuous IV infusion via a central venous catheter using an ambulatory infusion pump; may be administered temporarily using peripheral IV infusion during initiation until central access is established.
  • Each vial for single use only; any unused solution should be discarded.
  • Use immediately after reconstitution and immediate dilution to final concentration.
  • Infusion sets with an in-line 0.22-micron filter should be used.
  • To avoid potential interruptions in drug delivery, the patient should have immediate access to a backup infusion pump and IV infusion sets.
  • Do not mix Veletri(R) with any other parenteral medications or solutions prior to or during administration.
  • The ambulatory infusion pump should be small and lightweight, be able to adjust infusion rates in 2 ng/kg/min increments, have occlusion, end-of-infusion, and low-battery alarms, be accurate to +/-6% of the programmed rate, and be positive-pressure-driven (continuous or pulsatile) with intervals between pulses not exceeding 3 minutes at infusion rates used to deliver this drug.
  • The reservoir should be made of polyvinyl chloride, polypropylene, or glass.
  • The manufacturer product information should be consulted for appropriate infusion rates and further administration advice.

Storage requirements:
  • Unopened vials are stable until the date on the package when stored at room temperature in the carton and protected from light.
  • Avoid exposing diluted solutions to direct sunlight.
  • Refrigerated at 2C to 8C (35.6F to 46.4F) if not used immediately.
  • Do not freeze.
  • The manufacturer product information should be consulted for maximum administration of fully diluted solutions.

Reconstitution/preparation techniques:
  • Reconstitute Veletri(R) only as directed using sterile water for injection USP, or sodium chloride 0.9% injection USP.
  • Reconstitute Flolan(R) with the supplied diluent.
  • All products must be reconstituted as directed by the manufacturer of individual products; the manufacturer product information should be consulted for dilution instructions.

IV compatibility: The manufacturer product information should be consulted.

General:
  • Initiate in a setting with adequate personnel and equipment for physiologic monitoring and emergency care.
  • Except in life-threatening situations, (e.g., unconsciousness, collapse), infusion rates should only be adjusted under direction of a physician.

Monitoring:
  • Cardiovascular: Monitor blood pressure regularly during initiation and following dose changes; monitor standing and supine blood pressure and heart rate closely for several hours following dose adjustments.

Patient advice:
  • Adhere to sterile technique in preparing this drug for administration as well as in caring for the catheter.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by